Trials / Unknown
UnknownNCT04897854
Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer
TIming of Start of systemIc Treatment for Asymptomatic MEtastasized PANcreatic Cancer (TIMEPAN): a Randomized Controlled Multicenter Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 184 (estimated)
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Since patients with metastatic pancreatic cancer have a limited life expectancy, it is important to determine the timing of when to start chemotherapy in order to optimize the benefits of chemotherapy relative to the side effects. Therefore, two treatment strategies can be considered: chemotherapy started immediately at diagnosis, or delayed until disease-related symptoms occur.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Folfirinox | In both arms the intervention will be FOLRINIOX or nab paclitaxel in combination with gemcitabine per investigator's choice |
Timeline
- Start date
- 2021-04-22
- Primary completion
- 2024-04-22
- Completion
- 2024-04-22
- First posted
- 2021-05-24
- Last updated
- 2021-05-24
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04897854. Inclusion in this directory is not an endorsement.